Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.

[1]  Dominic P. Williams,et al.  Metabolism and bioactivation of clozapine by human liver in vitro. , 1995, The Journal of pharmacology and experimental therapeutics.

[2]  F. Guengerich,et al.  Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. , 1993, Archives of biochemistry and biophysics.

[3]  Y. Masubuchi,et al.  Mechanism-based inactivation of CYP2C11 by diclofenac. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[4]  Dominic P. Williams,et al.  The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. , 1995, The Journal of pharmacology and experimental therapeutics.

[5]  Christian Skonberg,et al.  Development and evaluation of an electrochemical method for studying reactive phase-I metabolites: correlation to in vitro drug metabolism. , 2007, Chemical research in toxicology.

[6]  T. Baillie,et al.  Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. , 2006, Chemical research in toxicology.

[7]  Zhengyin Yan,et al.  DETECTION OF A NOVEL REACTIVE METABOLITE OF DICLOFENAC: EVIDENCE FOR CYP2C9-MEDIATED BIOACTIVATION VIA ARENE OXIDES , 2005, Drug Metabolism and Disposition.

[8]  K. Ishak,et al.  Diclofenac‐associated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactions , 1995, Hepatology.

[9]  K. Albert,et al.  Isolation and identification of clozapine metabolites in patient urine. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[10]  N. Vermeulen,et al.  Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis. , 2007, Journal of medicinal chemistry.

[11]  N. Vermeulen,et al.  Rat liver microsomal cytochrome P450-dependent oxidation of 3,5-disubstituted analogues of paracetamol. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[12]  Gary W Caldwell,et al.  Stable-isotope trapping and high-throughput screenings of reactive metabolites using the isotope MS signature. , 2004, Analytical chemistry.

[13]  K. R. Marshall,et al.  P450 BM3: the very model of a modern flavocytochrome. , 2002, Trends in biochemical sciences.

[14]  M. Olkinuora,et al.  Agranulocytosis during treatment with clozapine , 1977, European Journal of Clinical Pharmacology.

[15]  T. Leemann,et al.  Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. , 1993, Life sciences.

[16]  S. Nelson,et al.  Mechanism of cytochrome P450 activation by caffeine and 7,8-benzoflavone in rat liver microsomes. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[17]  Yue Chen,et al.  IDENTIFICATION OF A NOVEL GLUTATHIONE ADDUCT OF DICLOFENAC, 4′-HYDROXY-2′-GLUTATHION-DESCHLORO-DICLOFENAC, UPON INCUBATION WITH HUMAN LIVER MICROSOMES , 2005, Drug Metabolism and Disposition.

[18]  E. Björnsson,et al.  Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden , 2005, Scandinavian Journal of Gastroenterology.

[19]  T. Baillie,et al.  Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. , 1999, Chemical research in toxicology.

[20]  N. Vermeulen,et al.  Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3. , 2006, Biochemical and biophysical research communications.

[21]  K. Midha,et al.  Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. , 1999, Chemico-biological interactions.

[22]  T. Baillie,et al.  Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[23]  T. Baillie,et al.  Mass spectrometry in the analysis of glutathione conjugates. , 1993, Biological Mass Spectrometry.

[24]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[25]  F. Guengerich,et al.  Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. , 1993, Chemical research in toxicology.

[26]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[27]  M. Davis,et al.  Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. , 1999, Chemical research in toxicology.

[28]  Zhengyin Yan,et al.  Screening for reactive intermediates and toxicity assessment in drug discovery. , 2006, Current opinion in drug discovery & development.

[29]  C. Hobbs,et al.  New cloning vectors and techniques for easy and rapid restriction mapping. , 1988, Gene.

[30]  N. Vermeulen,et al.  Paracetamol (Acetaminophen)-Induced Toxicity: Molecular and Biochemical Mechanisms, Analogues and Protective Approaches , 2001, Critical reviews in toxicology.

[31]  C. W. Fisher,et al.  Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies. , 1999, Mutation research.

[32]  V. Urlacher,et al.  Immobilisation of P450 BM‐3 and an NADP+ Cofactor Recycling System: Towards a Technical Application of Heme‐Containing Monooxygenases in Fine Chemical Synthesis , 2003 .